Drug Trial Radar · NCT04697628
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
Last checked: Nov 20, 2026Latest source record: Feb 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
502
Actual
Start
Feb 22, 2021
Primary completion
Jul 24, 2023
Study completion Jan 15, 2026
Sponsor
- Lead sponsor
- Seagen, a wholly owned subsidiary of PfizerPfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- Genmab
- First posted
- Jan 6, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is being done to find out whether tisotumab vedotin works better than chemotherapy to treat cervical cancer. People in this study have cervical cancer that has spread to other parts of the body (metastatic) or has come back after being treated (recurrent). Participants in this trial will be randomly assigned to one of two groups. One group will be treated with tisotumab vedotin. Participants in the other group will get one of five different chemotherapy drugs (topotecan, vinorelbine, gemcitabine, pemetrexed, or irinotecan). Participants and their doctors will know which group they are in. Participants in the chemotherapy group will decide with their study doctor which drug they will take.
Conditions
- Cervical Cancer
Interventions
tisotumab vedotinDrug
2.0 mg/kg every 3 weeks (Q3W)
topotecanDrug
1 or 1.25 mg/m2 intravenous (IV) on Days 1 to 5, every 21 days
vinorelbineDrug
30 mg/m2 IV on Days 1 and 8, every 21 days
gemcitabineDrug
1000 mg/m2 IV on Days 1 and 8, every 21 days
irinotecanDrug
100 or 125 mg/m2 IV weekly for 28 days, every 42 days
pemetrexedDrug
500 mg/m2 IV on Day 1, every 21 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: From randomization to date of death due to any cause or censoring date, whichever occurred first (maximum up to 25 months)
Locations
211 sites in 25 countries. Site status is shown where the registry gives one.
Arizona Oncology Associates, PC - HAL
Glendale, Arizona
Arizona Oncology Associates P.C. - NAHOA
Phoenix, Arizona
Arizona Oncology Associates, PC - HAL
Phoenix, Arizona
Arizona Oncology Associates, PC - HAL
Scottsdale, Arizona
Arizona Oncology Associates, PC - HAL
Tempe, Arizona
University of California Irvine Health
Irvine, California
UC Irvine Health (Investigator Site File Location)
Orange, California
University of California Irvine Health
Orange, California
Olive View - UCLA Medical Center
Sylmar, California
Yale University School of Medicine
New Haven, Connecticut
Broward Health Medical Center
Fort Lauderdale, Florida
Georgia Cancer Center at Augusta University
Augusta, Georgia
Northwestern Medical Group
Chicago, Illinois
Northwestern Memorial Hospital
Chicago, Illinois
Norton Cancer Institute, Downtown
Louisville, Kentucky
Norton Hospital
Louisville, Kentucky
Norton Cancer Institute, St. Matthews Campus, Attn. Becky Champion, PharmD
Louisville, Kentucky
Norton Cancer Institute, St. Matthews Campus
Louisville, Kentucky
Norton Cancer Institute
Louisville, Kentucky
Norton Women's & Children's Hospital
Louisville, Kentucky
Willis-Knighton Cancer Center Infusion Center
Shreveport, Louisiana
Willis-Knighton Physician Network/ Hematology-Oncology Associates
Shreveport, Louisiana
Willis-Knighton Physician Network/WK Gynecologic Oncology Associates
Shreveport, Louisiana
Willis-Knighton Physician Network/WK Gynecologic Oncology Associates
Shreveport, Louisiana
Minnesota Oncology Hematology PA
Coon Rapids, Minnesota
Minnesota Oncology Hematology, P.A
Coon Rapids, Minnesota
Minnesota Oncology Hematology, P.A
Edina, Minnesota
Minnesota Oncology Hematology, P.A
Maplewood, Minnesota
Minnesota Oncology Hematology, P.A
Minneapolis, Minnesota
Minnesota Oncology Hematology, P.A
Saint Paul, Minnesota
St. Dominic- Jackson Memorial Hospital Pharmacy Attn: Richard Wakefield
Jackson, Mississippi
Washington University School of Medicine- Obstetrics & Gynecology [Academic Offices]
St Louis, Missouri
Washington University School of Medicine [Patient Clinics]
St Louis, Missouri
Washington University School of Medicine-Obstetrics & Gynecology
St Louis, Missouri
NewYork Presbyterian - Brooklyn Methodist Hospital
Brooklyn, New York
NewYork Presbyterian - Queens
Flushing, New York
NewYork Presbyterian - Queens
Forest Hills, New York
Laura and Isaac Perlmutter Cancer Center at NYU Langone.
New York, New York
NYU Langone Medical Center
New York, New York
Cleveland Clinic Taussig Cancer Center Investigational Pharmacy
Cleveland, Ohio
Showing 40 of 211 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.